Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Drygin

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Nucleic Acids Research|December 18, 2004
Sequence-dependent cytotoxicity of second-generation oligonucleotidesDenis Drygin, Stephen Barone, C Frank Bennett
Annual Review of Pharmacology and Toxicology|January 9, 2010
The RNA polymerase I transcription machinery: an emerging target for the treatment of cancerDenis Drygin, William G Rice, Ingrid Grummt
Expert Opinion on Therapeutic Targets|July 19, 2013
Targeting RNA polymerase I transcription and the nucleolus for cancer therapyRoss D Hannan, Denis Drygin, Richard B Pearson
Oligonucleotides|July 2, 2005
Induction of toll-like receptors and NALP/PAN/PYPAF family members by modified oligonucleotides in lung epithelial carcinoma cellsDenis Drygin, Seongjoon Koo, Ranjan Perera, et al.
Drug Discovery Today|September 3, 2013
Targeting the nucleolus for cancer-specific activation of p53Denis Drygin, Sean E O'Brien, Ross D Hannan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2013
Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastomaYing Zheng, Braden C McFarland, Denis Drygin, et al.
Biomedicines|July 27, 2024
CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA LociDonald P Cameron, Jirawas Sornkom, Sameerh Alsahafi, et al.
Nature Structural Biology|January 7, 2003
Structure of the L1 protuberance in the ribosomeAlexei Nikulin, Irina Eliseikina, Svetlana Tishchenko, et al.
Journal of Clinical Pharmacology|May 14, 2026
Pharmacokinetics, Safety, and Tolerability of Anti-miR-17 Oligonucleotide RGLS4326 in Healthy Adult SubjectsTate Owen, Izaiah Cole, Denis Drygin, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2012
Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cellsFabrice Pierre, Collin F Regan, Marie-Claire Chevrel, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Nucleic Acids Research|December 18, 2004
Sequence-dependent cytotoxicity of second-generation oligonucleotidesDenis Drygin, Stephen Barone, C Frank Bennett
Annual Review of Pharmacology and Toxicology|January 9, 2010
The RNA polymerase I transcription machinery: an emerging target for the treatment of cancerDenis Drygin, William G Rice, Ingrid Grummt
Expert Opinion on Therapeutic Targets|July 19, 2013
Targeting RNA polymerase I transcription and the nucleolus for cancer therapyRoss D Hannan, Denis Drygin, Richard B Pearson
Oligonucleotides|July 2, 2005
Induction of toll-like receptors and NALP/PAN/PYPAF family members by modified oligonucleotides in lung epithelial carcinoma cellsDenis Drygin, Seongjoon Koo, Ranjan Perera, et al.
Drug Discovery Today|September 3, 2013
Targeting the nucleolus for cancer-specific activation of p53Denis Drygin, Sean E O'Brien, Ross D Hannan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2013
Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastomaYing Zheng, Braden C McFarland, Denis Drygin, et al.
Biomedicines|July 27, 2024
CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA LociDonald P Cameron, Jirawas Sornkom, Sameerh Alsahafi, et al.
Nature Structural Biology|January 7, 2003
Structure of the L1 protuberance in the ribosomeAlexei Nikulin, Irina Eliseikina, Svetlana Tishchenko, et al.
Journal of Clinical Pharmacology|May 14, 2026
Pharmacokinetics, Safety, and Tolerability of Anti-miR-17 Oligonucleotide RGLS4326 in Healthy Adult SubjectsTate Owen, Izaiah Cole, Denis Drygin, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2012
Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cellsFabrice Pierre, Collin F Regan, Marie-Claire Chevrel, et al.
Pageof 4